Verseon (LSE:VERS) Institutional Ownership : 22.20% (As of May. 24, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Verseon Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Verseon's institutional ownership is 22.20%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Verseon's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Verseon's Float Percentage Of Total Shares Outstanding is 0.00%.

Verseon Institutional Ownership Historical Data

The historical data trend for Verseon's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon Institutional Ownership Chart

Verseon Historical Data

The historical data trend for Verseon can be seen below:

	2019-02-28	2019-03-31	2019-04-30	2019-05-31	2019-06-30	2019-07-31	2019-08-31	2019-09-30	2019-10-31	2019-11-30
Institutional Ownership	22.80	27.74	22.22	22.22	22.20	22.20	22.20	22.20	22.20	22.20

Verseon Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Verseon (LSE:VERS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

47071 Bayside Parkway, Fremont, CA, USA, 94538

Website

http://www.verseon.com

Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.